Business UpdateJun 18, 2026, 07:06 AM
Kiora Pharma KIO-300 Suppresses Seizure Activity in Preclinical Epilepsy Model
AI Summary
Kiora Pharmaceuticals announced positive preclinical data for its ion channel modulator, KIO-300, demonstrating significant suppression of seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model. These findings, presented at the Epilepsy Foundation Pipeline Conference, suggest broad therapeutic potential beyond ophthalmology, where KIO-300 is the active ingredient in KIO-301, currently in Phase 2 for vision restoration. The company plans future R&D to explore additional neurological applications.
Key Highlights
- KIO-300 significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model.
- Treatment reduced spontaneous epileptiform event frequency, with statistically significant inhibition starting 42 minutes after treatment (p < 0.0001).
- Analysis of cumulative epileptiform burden also demonstrated a significant reduction following KIO-300 exposure (p < 0.0001).
- The suppressive effect persisted throughout both treatment and washout periods, suggesting prolonged neural tissue retention.
- KIO-300 did not impair broader electrical transmission in brain tissue, indicating specific effects on abnormal activity.
- KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase 2 clinical program in vision restoration.
Price Impact
More from KPRX